Esperion Therapeutics ESPR Tax Credit Carryforward Valuation Allowance
Tax Credit Carryforward Valuation Allowance at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's tax credit carryforward valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's tax credit carryforward valuation allowance?
- Esperion Therapeutics (ESPR) reported tax credit carryforward valuation allowance of $417.06M in Q4 2025.
- How has Esperion Therapeutics's tax credit carryforward valuation allowance changed year-over-year?
- Esperion Therapeutics's tax credit carryforward valuation allowance increased by 1.0% year-over-year, from $413.09M to $417.06M.
- What is the long-term trend for Esperion Therapeutics's tax credit carryforward valuation allowance?
- Over 5 years (2020 to 2025), Esperion Therapeutics's tax credit carryforward valuation allowance has grown at a 15.5% compound annual growth rate (CAGR), from $202.84M to $417.06M.
- What does tax credit carryforward valuation allowance mean?
- This is a contra-asset account that reduces the carrying value of tax credit carryforwards when it is more likely than not that some or all of the credits will not be realized. It reflects management's assessment of the company's ability to generate sufficient future taxable income. A high allowance suggests uncertainty regarding the realization of tax benefits.